



2020 was a year like no other with global issues including the COVID-19 pandemic, racial equity and political unrest. I am proud of the resiliency our team at Exelixis demonstrated during these challenging times, remaining more devoted than ever to continue building sustainable value and fulfilling our commitments to our patients, employees and our community.

As we strive to extend and improve the lives of people with cancer, we also recognize the need to contribute positively to society as a whole. With that in mind, I am pleased to provide an update on Exelixis' ESG initiatives. In this overview, we highlight the Company's sustainable business practices and the progress made in recent years to fulfill our commitments to our patients, employees and our community, including our continued efforts around our:

- Governance and compliance structure
- Commitment to maximizing innovation and access to our medicines, including our research and development (R&D) efforts and pricing principles
- Responsibility to produce safe, high-quality medicines for patients
- Efforts to incorporate environmentally sustainable practices into our operations
- Dedication to hiring and retaining talented employees and creating a safe, productive and supportive Company culture

As we look ahead, our focus remains on continued execution across the organization and doing so with the highest integrity. The importance of fully integrated ESG values is paramount to our credo as we strive to create sustained value for all our stakeholders by translating science into impact for patients and all those we serve.

We exist to give people hope – one drug, one patient at a time. I encourage you to read about our ESG activities to see all that has been accomplished in the past year through challenging circumstances, as well as our steadfast commitment to contributing to a more sustainable society.

Sincerely,

A handwritten signature in black ink, appearing to read "Michael Morrissey". The signature is fluid and cursive, with a large loop at the end.

Michael M. Morrissey, Ph.D.

President and Chief Executive Officer, Exelixis